Table of contents


On 4 December 2008, orphan designation (EU/3/08/589) was granted by the European Commission to Molecular Insight Pharmaceuticals GmbH, Germany, for yttrium (90Y) edotreotide for the treatment of gastro-entero-pancreatic neuroendocrine tumours.

The sponsorship was transferred to Molecular Insight Limited, United Kingdom, in June 2010 then to ITG Isotope Technologies Garching GmbH, Germany, in July 2013 and back to Molecular Insight Limited, United Kingdom, in January 2016.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2018 on request of the Sponsor.

Key facts

Active substance
Yttrium (90Y) edotreotide
Disease / condition
Treatment of gastro-entero-pancreatic neuroendocrine tumors
Date of decision
Orphan decision number

Sponsor's contact details

Molecular Insight Limited
Eversheds House
70 Great Bridgewater Street
Manchester M1 5ES
United Kingdom
Tel. +44 (0)845 497 8000
Fax: +44 (0)845 497 8888

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating